How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?
Atopic dermatitis (AD) is a heterogeneous disease in terms of its phenotypical, barrier, and immunological presentation. Emerging therapies are undoubtedly contributing to a new chapter in the treatment of AD, bringing an excellent possibility of individualization, and thereby creating a tailored ap...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/8/7557 |
| _version_ | 1797605021597040640 |
|---|---|
| author | Alicja Mesjasz Karol Kołkowski Andreas Wollenberg Magdalena Trzeciak |
| author_facet | Alicja Mesjasz Karol Kołkowski Andreas Wollenberg Magdalena Trzeciak |
| author_sort | Alicja Mesjasz |
| collection | DOAJ |
| description | Atopic dermatitis (AD) is a heterogeneous disease in terms of its phenotypical, barrier, and immunological presentation. Emerging therapies are undoubtedly contributing to a new chapter in the treatment of AD, bringing an excellent possibility of individualization, and thereby creating a tailored approach. The two most promising substance groups are biological drugs (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and Janus kinase inhibitors (JAKis) (baricitinib, upadacitinib, and abrocitinib). The vision that certain well-defined phenotypes and endotypes, as well as personal preferences, may guide the future treatment of AD is both tempting and appealing, but not yet reality. The accessibility of new drugs such as biologics and small molecules has opened up the discussion regarding personalized medicine, referring to the complex nature of AD as well as the experiences from clinical trials and real-world evidence. We have now reached the point of creating new strategies and AD treatment goals by increasing the amount of new information concerning the efficacy and safety of new drugs. This article has reviewed the novel treatment options for AD in the light of the heterogeneity of this disease and proposes a broader vision on the strategy of personalized treatment of AD. |
| first_indexed | 2024-03-11T04:55:12Z |
| format | Article |
| id | doaj.art-7f63ff50bb6e44cb8cda2f735e7ed151 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T04:55:12Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-7f63ff50bb6e44cb8cda2f735e7ed1512023-11-17T19:42:17ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-04-01248755710.3390/ijms24087557How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?Alicja Mesjasz0Karol Kołkowski1Andreas Wollenberg2Magdalena Trzeciak3Dermatological Students Scientific Association, Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, PolandDermatological Students Scientific Association, Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, PolandDepartment of Dermatology, Venereology and Allergology, University Hospital, Ludwig Maximilian University, Frauenlobstr. 9-11, 80337 Munich, GermanyDepartment of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, 80-214 Gdansk, PolandAtopic dermatitis (AD) is a heterogeneous disease in terms of its phenotypical, barrier, and immunological presentation. Emerging therapies are undoubtedly contributing to a new chapter in the treatment of AD, bringing an excellent possibility of individualization, and thereby creating a tailored approach. The two most promising substance groups are biological drugs (dupilumab, tralokinumab, lebrikizumab, nemolizumab) and Janus kinase inhibitors (JAKis) (baricitinib, upadacitinib, and abrocitinib). The vision that certain well-defined phenotypes and endotypes, as well as personal preferences, may guide the future treatment of AD is both tempting and appealing, but not yet reality. The accessibility of new drugs such as biologics and small molecules has opened up the discussion regarding personalized medicine, referring to the complex nature of AD as well as the experiences from clinical trials and real-world evidence. We have now reached the point of creating new strategies and AD treatment goals by increasing the amount of new information concerning the efficacy and safety of new drugs. This article has reviewed the novel treatment options for AD in the light of the heterogeneity of this disease and proposes a broader vision on the strategy of personalized treatment of AD.https://www.mdpi.com/1422-0067/24/8/7557atopic dermatitismonoclonal antibodiesJAK inhibitors |
| spellingShingle | Alicja Mesjasz Karol Kołkowski Andreas Wollenberg Magdalena Trzeciak How to Understand Personalized Medicine in Atopic Dermatitis Nowadays? International Journal of Molecular Sciences atopic dermatitis monoclonal antibodies JAK inhibitors |
| title | How to Understand Personalized Medicine in Atopic Dermatitis Nowadays? |
| title_full | How to Understand Personalized Medicine in Atopic Dermatitis Nowadays? |
| title_fullStr | How to Understand Personalized Medicine in Atopic Dermatitis Nowadays? |
| title_full_unstemmed | How to Understand Personalized Medicine in Atopic Dermatitis Nowadays? |
| title_short | How to Understand Personalized Medicine in Atopic Dermatitis Nowadays? |
| title_sort | how to understand personalized medicine in atopic dermatitis nowadays |
| topic | atopic dermatitis monoclonal antibodies JAK inhibitors |
| url | https://www.mdpi.com/1422-0067/24/8/7557 |
| work_keys_str_mv | AT alicjamesjasz howtounderstandpersonalizedmedicineinatopicdermatitisnowadays AT karolkołkowski howtounderstandpersonalizedmedicineinatopicdermatitisnowadays AT andreaswollenberg howtounderstandpersonalizedmedicineinatopicdermatitisnowadays AT magdalenatrzeciak howtounderstandpersonalizedmedicineinatopicdermatitisnowadays |